This Investor Exited a $22 Million GRAIL Stake Before a 50% One-Day Stock Crash Last Month

One Fin Capital fully exited its GRAIL (NASDAQ:GRAL) stake, selling ~380,000 shares worth $22.47M and cutting the position from ~7.4% of the fund's 13F AUM to 0%. GRAIL shares trade at $46.84 (up 68% Y/Y); TTM revenue was $147.2M and net loss $408.35M, and a roughly 50% single-day drop after earnings underscores regulatory/adoption and execution risk. After the filing the fund's top 13F holdings are COF $31.88M (12.1% AUM), NXT $26.13M (9.9%), RKT $25.75M (9.8%), DRVN $24.30M (9.2%) and NSC $23.10M (8.8%).

Analysis

One Fin’s exit is a liquidity event that magnifies two structural vulnerabilities in the GRAIL story: patient/payer adoption uncertainty and headline-driven sentiment. Diagnostic leaders live and die on incremental reimbursement decisions and guideline endorsements — outcomes that materialize on quarters-to-years timelines and create binary moves that wipe out rich multiple expansion in hours.

A concentrated manager de-risking also reallocates into lower-volatility, cash-flow names; expect short-term bid pressure for cyclical/growth-compressed names (beneficiaries: consumer-financials and mortgage/servicing businesses) as systematic funds rebalance away from high single-stock concentration. That flow dynamic elevates realized and implied volatility in GRAL, creating a window where directional options can be sized with capped risk.

Second-order winners and losers extend beyond peers: sequencing and lab-capacity vendors will see demand re-steer if commercial Galleri rollouts slow, while providers and integrated health systems could spend less on screening programs if reimbursement lags. The path to value is multi-year (regulatory/coverage → adoption → substitute testing effects); near-term traders should treat GRAL as event-driven volatility, not steady growth exposure.

Key Decisions for Investors

• Pair trade (3–6 month horizon): Long COF and RKT equal-weight (1.0–1.5% portfolio each) funded by a GRAL 3-month put spread (buy a deeper put / sell a nearer put to cut cost). Rationale: capture flow into cash-generative, under-owned names while capping downside on GRAL exposure; target asymmetric payoff where a 30–50% negative regulatory or adoption surprise on GRAL produces 3x+ on the put spread while COF/RKT deliver stable income and 10–25% upside on normalization.
• Event hedge (short-term, 1–3 months): Buy GRAL 1–3 month ATM puts sized to limit downside to 1% of portfolio value. Use these as pure insurance ahead of any upcoming reimbursement/regulatory readouts; payoff if sentiment reverts sharply again, with limited known cost and defined loss if no adverse event occurs.
• Volatility sell/relative value (2–8 weeks): If GRAL implied vol spikes >70% and realised vol stays lower, sell a small size of calendar spreads (near-dated vol short, 2–3 month vol long) to monetize premium while keeping exposure limited to pin risk. This is tactical income — cap net gamma and monitor for catalyst windows to close position quickly.
• Contrarian, optionality buy (6–12 months): If you want exposure to upside clinical/regulatory success without outright equity risk, purchase a modest GRAL call spread (out-of-the-money, long-dated) sized at <0.5% portfolio. This captures the tail gain if coverage/adoption surprises positively while keeping loss limited to option premium.